Payment overview · 2025
General Payments
$4,471.52
123 reported records · 20 companies
Healthcare provider profile · identity verified
Ediz Tasan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · PASCAGOULA, MS · NPI 1053670166
Verified facts
What the public records show
CMS Open Payments records show Ediz Tasan, M.D. received $4,471.52 in general payments during 2025 across 123 reported records.
AngioDynamics, Inc. accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $1,200.00 | 26.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $967.89 | 21.6% | 31 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$866.07 | 19.4% | 33 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $374.50 | 8.4% | 18 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $193.79 | 4.3% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $140.73 | 3.1% | 8 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $116.03 | 2.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $108.64 | 2.4% | 4 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $100.63 | 2.2% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $76.78 | 1.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.31 | 1.6% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $50.28 | 1.1% | 2 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $44.89 | 1.0% | 2 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $39.22 | 0.9% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $36.36 | 0.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $24.92 | 0.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.39 | 0.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.82 | 0.3% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $15.39 | 0.3% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $13.88 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,271.52 | 122 |
| Long term medical supply or device loan | $1,200.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $1,200.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Structural Heart Normalized: general structural heart |
Device | Boston Scientific Corporation | $513.58 | 19 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $374.50 | 18 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $229.10 | 2 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $174.77 | 5 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $165.97 | 8 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $132.00 | 4 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $123.82 | 5 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $120.07 | 6 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $116.03 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $87.85 | 3 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $85.08 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $80.15 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $75.02 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.31 | 4 | 2025 |
Source payment records
|
|||||
| VersaCross Large Access Solution Normalized: versacross large access solution |
Device | Boston Scientific Corporation | $65.28 | 2 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $43.75 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $43.31 | 3 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $39.22 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $36.62 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $36.36 | 1 | 2025 |
Source payment records
|
|||||
| ATTAIN COMMAND + SUREVALVE Normalized: attain command surevalve |
Device | Medtronic, Inc. | $33.13 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $33.03 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $24.92 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| Pioneer Normalized: pioneer |
Device | Philips North America LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| NC Emerge Normalized: nc emerge |
Device | Boston Scientific Corporation | $12.68 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $12.41 | 1 | 2025 |
Source payment records
|
|||||
| VIABAHN Endoprosthesis with PROPATEN Bioactive Surface Normalized: viabahn endoprosthesis with propaten bioactive surface |
Device | W. L. Gore & Associates, Inc. | $12.15 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $10.89 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $6.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
266 | 62 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
107 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 325 | 122 |
| Clopidogrel | Clopidogrel Bisulfate | 274 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 96 |
| Eliquis | Apixaban | 266 | 62 |
| Carvedilol | Carvedilol | 250 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 63 |
| Lisinopril | Lisinopril | 160 | 52 |
| Losartan Potassium | Losartan Potassium | 133 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 39 |
| Entresto | Sacubitril/Valsartan | 107 | 32 |
| Potassium Chloride | Potassium Chloride | 83 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 27 |
| Xarelto | Rivaroxaban | 70 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 16 |
| Warfarin Sodium | Warfarin Sodium | 54 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | 16 |
| Spironolactone | Spironolactone | 49 | 22 |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Ranolazine Er | Ranolazine | 45 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 14 |
| Sotalol | Sotalol Hcl | 36 | 12 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Torsemide | Torsemide | 32 | 11 |
| Valsartan | Valsartan | 26 | suppressed |
| Metolazone | Metolazone | 25 | 13 |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | 11 |
| Brilinta | Ticagrelor | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,471.52 · 123 records | AngioDynamics, Inc. | ASSURITY, ATTAIN COMMAND + SUREVALVE, AVEIR, AVVIGO Guidance System, Acticor 7 VR-T DX, Auryon Laser System 100-120 Vac, Barostim Neo System, CAMZYOS, CLEVIPREX, CLOTTRIEVER BOLD CATHETER, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, CVI Systems, DIAMONDBACK PERIPHERAL, ESPRIT, FLOWTRIEVER, GORE VIABAHN Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, General - Structural Heart, General - Therapies, HAWKONE, Hillrom - Carnation Ambulatory Monitor, IN.PACT ADMIRAL, JARDIANCE, KENGREAL, LEQVIO, LINQ II, Labosys, LifeVest, MICRA, MYCARELINK, NC Emerge, ONYX FRONTIER, Pioneer, REPATHA, RotarexS 6 F x 135 cm, SELECTSECURE, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VENASEAL, VIABAHN Endoprosthesis with PROPATEN Bioactive Surface, VersaCross Large Access Solution, WATCHMAN Access System | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error